We have gathered all available information on the 2023 EIC programme, covering deadlines, budgets, consortia & more in a single guide. A must-read if you’re considering applying for EIC funding to finance your research, R&D or commercialization project.
At Catalyze, we have obtained funding from the EIC subprogrammes for a wide range of companies, legal entities and academic groups.
3 subprogrammes form the basis of the EIC programme:
In continuation of the first work programme, both open topic calls and specific challenge-driven calls are available for EIC Pathfinder, EIC Transition and EIC Accelerator. The challenge-driven approach provides funding to address specific technological and innovation breakthroughs. The challenges focus on EU priorities for transitioning to a green, digital and healthy society, as well as the overall strategic planning for Horizon Europe. Each instrument is divided over Open calls and Challenge-driven calls.
In our EIC 2023 Programme Guide we have gathered all available information for you. We assembled the information on deadlines, budgets, consortia & more in a single guide. A must read if you’re looking for new funding opportunities for your research, R&D or commercialization project.
Read on to find out how the MAX-fresh consortium obtained €2.2 million from the Fast ...
Plantics is revolutionizing the future of biodegradable plastics with cost-effective ...
Funding research projects of consortia with a mix of partners from academia and companies, advancing research to develop the scientific basis to underpin breakthrough technologies.
Funding consortia of academia and companies, to validate technologies and develop business plans for specific applications. This is a newly added instrument to the EIC programme. Only grantees of ERC Proof of Concept or EIC Pathfinder or FET are eligible to submit an application to this instrument.
Focusing on supporting companies (SMEs, start-ups, spin-outs and in exceptional cases small mid-caps) to bring their innovations to market and scale up.
Achilles Therapeutics (UK) is pushing the frontier of personalized adoptive T cell therapies. In the first round of the 2022 EIC Pathfinder program, an Achilles-led consortium was awarded €4 million from the “Emerging technologies in cell & gene therapy” Challenge, to develop a proof-of-concept, first-in-class, smart bioprocessing manufacturing platform.
A must-have if you’re interested in getting your business to the next level